




## RNAi Therapeutics

Chikujee Therapeutics has developed significant and growing intellectual property assets related to RNAi technologies, including compositions of matter, methods of use, manufacturing and purification processes and routes of delivery. Chikujee is in the process of filing or exclusively licensing a broad suite of US patents and patent applications for development and delivery of RNAi therapeutics, with counterparts filed in Europe, Japan and other key countries. We have, to our knowledge, the earliest priority date on a very broad patent application covering methods and compositions for therapeutic delivery and use of RNAi.

Chikujee Therapeutics is a biopharmaceutical company focused on creating targeted therapeutics using its patented and proprietary NanoBindi-based TSDV technologies for the development of nanoparticle drug formulations. Chikujee's initial emphasis has been to bring targeted siRNA and small molecule therapeutics to the clinic for oncology applications; however, the technologies are not limited to these classes of molecules and are applicable to a very broad range of therapeutic entities and diseases.



The Chikujee technology for RNAi, called NanoRISC™ (nanoBindi enabled-RNAi Induced Silencing Complex), overcomes the significant hurdles to efficient, systemic delivery of siRNA. Chikujee's technology for siRNA therapeutics:

- Allows for repeat dosing without the risk of immune reactions
- Has demonstrated efficient, targeted delivery in animal models
- Has overcome the extra- and intra-cellular barriers to siRNA delivery
- Has been scaled-up and manufactured for clinical use


In addition to the RNAi technologies and pipeline, Chikujee has a therapeutic pipeline that involves small molecule drugs. This technology, called NanoRISC™, leads to designed nanoparticle therapeutics that:

- Greatly enhance solubilization of low solubility molecules
- Provide for long circulation in humans (half life of ca. 40 hours) by designed modulation of absorption, distribution, metabolism and excretion



- Target specific disease tissues
- Have controlled and tunable drug release profiles to match mechanism of action

In addition to focusing on therapeutic pipelines, Chikujee's patented and proprietary delivery systems have utility in application areas not internally pursued by Chikujee. Consequently, we are continually exploring additional opportunities to combine our delivery systems with companies seeking delivery solutions.



**Products For:**

**CNS**

**Liver**